HLTRF (HLS Therapeutics) ROE % Adjusted to Book Value : -22.15% (As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics ROE % Adjusted to Book Value?

HLS Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -23.92%. HLS Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 1.08. HLS Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -22.15%.

HLS Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for HLS Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics ROE % Adjusted to Book Value Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-3.51

-3.39

-3.41

-8.82

-19.60

HLS Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-21.40	-17.19	-23.57	-28.15	-22.15

Competitive Comparison of HLS Therapeutics's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's ROE % Adjusted to Book Value falls into.

HLS Therapeutics ROE % Adjusted to Book Value Calculation

HLS Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-24.69%	/	1.26
	=	-19.60%

HLS Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-23.92%	/	1.08
	=	-22.15%

HLS Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

HLS:Canada

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.